Zhao Qingyi, Yang Na, Gu Xinxi, Li Yuanyuan, Teng Da, Hao Ya, Lu Haiqiang, Mao Ruoyu, Wang Jianhua
Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
Innovative Team of Antimicrobial Peptides and Alternatives to Antibiotics, Feed Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
Mar Drugs. 2023 Dec 20;22(1):8. doi: 10.3390/md22010008.
The marine peptide, American oyster defensin (AOD), is derived from and exhibits a potent bactericidal effect. However, recombinant preparation has not been achieved due to the high charge and hydrophobicity. Although the traditional fusion tags such as Trx and SUMO shield the effects of target peptides on the host, their large molecular weight (12-20 kDa) leads to the yields lower than 20% of the fusion protein. In this study, a short and acidic fusion tag was employed with a compact structure of only 1 kDa. Following 72 h of induction in a 5 L fermenter, the supernatant exhibited a total protein concentration of 587 mg/L. The recombinant AOD was subsequently purified through affinity chromatography and enterokinase cleavage, resulting in the final yield of 216 mg/L and a purity exceeding 93%. The minimum inhibitory concentrations (MICs) of AOD against , , and ranged from 4 to 8 μg/mL. Moreover, time-killing curves indicated that AOD achieved a bactericidal rate of 99.9% against the clinical strain G-81 within 0.5 h at concentrations of 2× and 4× MIC. Additionally, the activity of AOD was unchanged after treatment with artificial gastric fluid and intestinal fluid for 4 h. Biocompatibility testing demonstrated that AOD, at a concentration of 128 μg/mL, exhibited a hemolysis rate of less than 0.5% and a cell survival rate of over 83%. Furthermore, AOD's in vivo therapeutic efficacy against mouse subcutaneous abscess revealed its capability to restrain bacterial proliferation and reduce bacterial load, surpassing that of antibiotic lincomycin. These findings indicate AOD's potential for clinical usage.
海洋肽美国牡蛎防御素(AOD)来源独特,具有强大的杀菌作用。然而,由于其高电荷和疏水性,尚未实现重组制备。尽管传统的融合标签如Trx和SUMO可屏蔽目标肽对宿主的影响,但其较大的分子量(12 - 20 kDa)导致融合蛋白产量低于20%。在本研究中,采用了一种结构紧凑、仅1 kDa的短酸性融合标签。在5 L发酵罐中诱导72小时后,上清液中总蛋白浓度为587 mg/L。随后通过亲和层析和肠激酶切割对重组AOD进行纯化,最终产量为216 mg/L,纯度超过93%。AOD对金黄色葡萄球菌、大肠杆菌和铜绿假单胞菌的最低抑菌浓度(MIC)范围为4至8 μg/mL。此外,时间杀菌曲线表明,在2倍和4倍MIC浓度下,AOD在0.5小时内对临床菌株G - 81的杀菌率达到99.9%。此外,AOD在人工胃液和肠液中处理4小时后活性不变。生物相容性测试表明,浓度为128 μg/mL的AOD溶血率低于0.5%,细胞存活率超过83%。此外,AOD对小鼠皮下脓肿的体内治疗效果显示其能够抑制细菌增殖并降低细菌载量,优于抗生素林可霉素。这些发现表明AOD具有临床应用潜力。